Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure.
Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure.
复制标题
局部应用丝裂霉素 C 预防激光鼓膜切开术闭合的剂量-反应关系。
DOI：
10.1016/s0194-59980301394-9
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Buchman,CraigA
中科院分区：
文献类型：
--
作者：
Jassir,David;Odabasi,Onur;Gomez-Marin,Orlando;Buchman,CraigA
目的：我们试图确定局部丝裂霉素C的剂量-反应曲线时，用于延长通畅性的激光辅助myringotomies.Study设计和设置：双侧myringotomies进行使用氩激光在40只豚鼠与正常的耳朵。局部应用含（0.05、0.2、0.4或2.0 mg/mL）丝裂霉素C的纱布。监测包括每周或每两周otomicroscopy.RESULTS：在以前的研究中，所有盐水治疗鼓膜切开术关闭的第7天。到第14天，0.05 mg/mL组的所有鼓膜切开术（100%）均已关闭。相比之下，0.2和0.4 mg/mL治疗组中所有鼓膜切开术（100%）在第14天保持通畅，2.0 mg/mL组中56%的鼓膜切开术保持通畅。到第56天，2.0 mg/mL组中所有鼓膜切开术均闭合，0.4 mg/mL组中5例（50%）鼓膜切开术通畅，0.2 mg/mL组中1例（11%）鼓膜切开术通畅。研究在第84天（12周）终止。当时，仅0.4 mg/mL组鼓膜切开术通畅（n = 3; 30%）。最高剂量（2.0 mg/mL）的丝裂霉素与耳畸形显著相关。耳鼻喉也似乎与早期鼓膜切开术closure.CONCLUSION：局部丝裂霉素C用于延长鼓膜切开术通畅性时，剂量高达0.4 mg/mL的剂量反应曲线。更高剂量似乎不会延长通畅性，并与更大的耳畸形相关，表明中耳毒性。
OBJECTIVE:We sought to determine a dose-response curve for topical mitomycin C when used to prolong the patency of laser-assisted myringotomies.STUDY DESIGN AND SETTING:Bilateral myringotomies were performed using the argon laser in 40 guinea pigs with normal ears. Pledgets with (0.05, 0.2, 0.4, or 2.0 mg/mL) mitomycin C were applied topically. Monitoring consisted of weekly or biweekly otomicroscopy.RESULTS:As in previous studies, all saline-treated myringotomies closed by day 7. By day 14, all myringotomies (100%) in the 0.05 mg/mL group were closed. By contrast, all myringotomies (100%) remained patent in the 0.2 and 0.4 mg/mL treatment groups, and 56% of the myringotomies remained patent in the 2.0 mg/mL group at day 14. By day 56, all myringotomies were closed in the 2.0 mg/mL group, 5 (50%) myringotomies were patent in the 0.4 mg/mL group, and 1 (11%) myringotomy was patent in the 0.2 mg/mL group. The study was terminated on day 84 (12 weeks). At that time, only the 0.4 mg/mL group had patent myringotomies (n = 3; 30%). The highest dose (2.0 mg/mL) of mitomycin was significantly associated with otorrhea. Otorrhea also appeared to be associated with earlier myringotomy closure.CONCLUSION:There is a dose-response curve for topical mitomycin C when used for prolonging my-ringotomy patency in doses up to 0.4 mg/mL. Higher doses do not appear to prolong patency and are associated with greater otorrhea, suggesting middle ear toxicity.